Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows

Evaluate the expected performance of Novartis (NVS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

On October 27, Novartis will report its results for the third quarter. As a reminder, its Q2 revenue rose 10.6% quarter-over-quarter to $14.95 billion, primarily due to the strong performance of the oncology portfolio and Cosentyx. On September 18, 2026, the EMA's CHMP adopted a positive opinion recommending approval of Cosentyx for patients suffering from polymyalgia rheumatica.

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.